|
|
|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
Financial Markets Research: ASCO 2006 Review Part I
ASCO features key presentations in the oncology area, and is generally the most important week of the year for oncology. Presents Datamonitor’s comments on the most important events at the 2006 conference.
Financial Markets Research: Santarus, Inc.s Zegerid
Following the lackluster 2004 launch of an oral suspension formulation of Santarus’ lead product, Zegerid (a fast-acting proton pump inhibitor) much of Santarus’ future success is tied to the commercial potential for the recently launched
Financial Markets Research: Renovis, Inc.s NXY-059
Renovis and AstraZeneca’s NXY-059 is viewed as the most promising neuroprotectant currently in development for stroke, however, much of its potential is dependent upon its ability to demonstrate a benefit in the recently enrolled SAINT-II trial.
Financial Markets Research: Bausch & Lombs Withdrawal
In May 2006 Bausch & Lomb’s ReNu with MoistureLoc contact lens solution was permanently withdrawn from markets worldwide due to an outbreak of a fungal eye infection. For a large market player, the loss of a new revenue driver and the negative p
Financial Markets Research: Sirona Dental Systems
Digital imaging products and CEREC form the basis for growth for Sirona Dental Systems, while accounting for nearly two-thirds of revenues, and will therefore be essential to the newly formed combination of Schick Technologies and Sirona.
Financial Markets Research: Indevus Pharmaceuticals Sanctura XR
The lack of differentiation between overactive bladder agents has led manufacturers to turn to large-scale marketing efforts in an attempt to gain market share. Given the relatively small marketing capabilities of IDEV and Esprit, they may have diffic
Results 1 - 10 of 10
|
|
|
|
